Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Use of CDK inhibitor for the treatment of glioma
US8946226B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8946226-B2 |
| Application number | US-200913055533-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 28, 2009 |
| Priority date | Jul 29, 2008 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a low molecular weight ATP-competitive CDK inhibitor able to cross the blood brain barrier for use in the treatment of malignant glioma and, in particular, of glioblastoma. The compound can be administered together with one or more agents selected from the group consisting of cytotoxic or cytostatic agents and ionizing radiation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a malignant glioma, the method comprising administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more antineoplastic agents, wherein the agent is temozolomide. 2. The method according to claim 1 wherein the malignant glioma is a glioblasto…
Assignees
Inventors
Classifications
- A61K31/519Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8946226B2 cover?
- The invention provides a low molecular weight ATP-competitive CDK inhibitor able to cross the blood brain barrier for use in the treatment of malignant glioma and, in particular, of glioblastoma. The compound can be administered together with one or more agents selected from the group consisting of cytotoxic or cytostatic agents and ionizing radiation.
- Who is the assignee on this patent?
- Ciomei Marina, Fiorentini Francesco, Pesenti Enrico, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).